MedMira Rapid HIV Test is the Choice of Internationally Renowned Medical Institutes

MedMira Rapid HIV Test is the Choice of Internationally Renowned
Medical Institutes
Recent Study Indicates Need for Increased Rapid HIV Testing In America 


HALIFAX, Feb. 15  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow- through
diagnostic technology, today announced that internationally renowned Stanford
Medical University, Duke Medical University and Johns Hopkin's Medical Research
University are currently using MedMira's FDA approved Reveal(TM) G2 Rapid HIV-1
Antibody Test's (Reveal(TM) G2) in their central labs. These leading medical
research universities have chosen Reveal(TM) G2 over other FDA- approved rapid
HIV tests after routine evaluations. A recently released report by Stanford and
Duke Universities shows the cost benefits of increased national HIV testing in
the United States.

MedMira had announced previously that Reveal(TM) G2 was the number one choice
for U.S. hospitals for the second year running, based on results of an
independent United States CDC study (January 18th, 2005). While rapid HIV
testing is still an emerging market in the U.S., MedMira's Reveal(TM) G2 has
quickly become the leading rapid HIV test in U.S. hospitals due to its ease of
use and quick time to obtain test results (only 3 minutes), compared to the
other FDA-approved tests which require 10 to 40 minutes to obtain results.

With a China CDC study placing MedMira's rapid test as number one for quality
and consistency of results and the South African Medical Research Council's
recent rating of MedMira's MiraWell(TM) HIV Test as the primary test of choice,
MedMira is gaining a strong international reputation in the global healthcare
market. MedMira's most recent advancement was the launch of its Over the
Counter (OTC) MiraCare(TM) Rapid HIV Test in Hong Kong and Macao (released
January 24th, 2005).

Says Hermes Chan, president and COO of MedMira "Our line of rapid HIV tests
continues to receive the highest marks in trials and evaluations worldwide;
from countries with highly respected healthcare systems, like the United
States, China and South Africa, to smaller nations with very little
infrastructure." Chan continues, "This recent study by Stanford and Duke
Universities proves that the need for rapid HIV testing is increasing and
MedMira is confident that we will continue to lead the way in providing
reliable rapid HIV testing products to the world."

MedMira is the only rapid HIV test manufacturer in the world to receive
regulatory approvals from the U.S. FDA, Health Canada and the Chinese SFDA.
Other leading health units around the world using MedMira's rapid HIV tests
include the Canadian Armed Forces, United States Marine Corps, China Provincial
Blood Banks, Stanford Medical University, Duke Medical University and Johns
Hopkin's Medical Research University.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-though
rapid diagnostic tests for the clinical laboratory market. MedMira's tests
provide reliable, rapid diagnosis in just 3 minutes for the detection of human
antibodies in human serum, plasma or whole blood for diseases such as HIV. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For
more information visit MedMira's website at http://www.medmira.com/.

MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available.

MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada with a representative
office in Beijing, China.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: Investor Relations, Dr. James Smith: [phone] or e-mail:

Copyright